论文部分内容阅读
为观察还原型谷胱甘肽（ＴＡＤ）治疗各型病毒性肝炎的疗效，我们选择３３０例患者，按观察方案随机配对２００例（治疗组和对照组各１００例），治疗组另扩展１３０例。包括ＡＩＨ、ＣＡＨ、ＣＳＨ和ＬＣ。两组病例具有可比性。两组基础治疗相同，治疗组用ＴＡＤ０．６４６ｇ，每日一次，静滴，疗程２０天至６０天。结果发现ＴＡＤ对各型病毒性肝炎的显效率均明显高于对照组，且平均恢复时间均明显短于对照组，治疗组总有效率达９１．３％，其中显效率达７６．５％，均明显高于对照组。ＴＡＤ治疗无明显不良反应。提示ＴＡＤ可作为治疗病毒性肝炎的有效辅助治疗药物。
To observe the efficacy of reduced glutathione (TAD) in the treatment of various types of viral hepatitis, we selected 330 patients who were randomized according to the observation protocol to 200 patients (100 in each of the treatment group and the control group). The treatment group was further expanded with 130 patients . Including AIH, CAH, CSH and LC. Two groups of patients are comparable. Two groups of the same basic treatment, the treatment group with TAD0.646g, once daily, intravenous infusion, the course of 20 days to 60 days. The results showed that the significant efficiency of TAD for various types of viral hepatitis was significantly higher than the control group, and the average recovery time was significantly shorter than the control group, the treatment group, the total effective rate was 91.3%, of which markedly effective rate of 76.5% Were significantly higher than the control group. TAD treatment without significant adverse reactions. Tip TAD can be used as an effective adjuvant therapy for the treatment of viral hepatitis.